天津医药 ›› 2015, Vol. 43 ›› Issue (4): 422-425.doi: 10.11958/j.issn.0253-9896.2015.04.024

• 应用研究 • 上一篇    下一篇

国产BuMA 支架术后支架血栓及主要临床事件随访分析

黄奎1,2,于玮玮2,吕威颖1,刘寅1,2△   

  1. 1天津医科大学研究生院(邮编300070);2天津市胸科医院心内科
  • 收稿日期:2014-10-16 修回日期:2015-01-29 出版日期:2015-04-15 发布日期:2015-04-13
  • 通讯作者: 刘寅 E-mail:liuyin2088@163.com
  • 作者简介:黄奎(1985),男,硕士在读,主要从事冠心病介入治疗研究

Stent thrombosis and major clinical events after BuMA coronary stent implantation

HUANG Kui1, 2, YU Weiwei2, LYU Weiying1, LIU Yin1, 2△   

  1. 1 Graduate School of Tianjin Medical University, Tianjin 300070, China; 2 Department of cardiology, Tianjin Chest Hospital
  • Received:2014-10-16 Revised:2015-01-29 Published:2015-04-15 Online:2015-04-13
  • Contact: LIU Yin E-mail:liuyin2088@163.com

摘要: 摘要:目的探讨植入国产生物降解药物涂层冠状动脉BuMA 支架治疗冠心病的远期安全性及有效性。方法选择同期植入BuMA 支架及Resolute 支架的冠心病患者分别作为观察组(440 例)和对照组(460 例),2 组临床基线情况、冠脉造影(CAG)病变情况及经皮冠脉介入治疗(PCI)相关指标均无明显差别。对患者进行平均(24±4)个月随访,随访主要终点事件为发生明确的或很可能的支架血栓(ST);次要终点事件为主要心脏不良事件(MACEs),包括再发心绞痛、急性非致死性心肌梗死、死亡、靶血管血运重建(TVR)的复合终点;其他终点事件为全因死亡、心源性死亡、心肌梗死(MI)、靶病变血运重建(TLR)、非靶血管血运重建及卒中。观察组失访5 例,对照组失访26 例。结果观察组435 例患者共植入615 枚支架,对照组434 例患者共植入614 枚支架,2 组均平均植入1.41 枚/例。2 组主要终点[1.4%(6/435) vs 1.8%(8/434),χ2=0.087]、次要终点[12.3%(54/435) vs 10.8%(47/434),χ2=0.524]及其他终点事件发生率的差异均无统计学意义。结论国产BuMA 支架具有良好的远期安全性及有效性。

关键词: 药物洗脱支架, 冠心病, 冠状血管造影术, 血管成形术, 经腔, 经皮冠状动脉, 支架血栓

Abstract: Abstract: Objective To investigate the long-term safety and efficacy of the domestic biodegradable drug-eluting cor⁃ onary stents (BuMA) in treating coronary heart disease (CHD). Methods Patients (n=440) who received BUMA stents were designated as observation group while patients (n=460) received Resolutestents were designated as control group. The base⁃ line clinical characteristics, extend of pathological change shown by Coronary Arteriography (CAG),the procedure of percu⁃ taneous coronary intervention were similar between these two groups. The patients were followed up for a mean of 24±4 months; the primary endpoint was the occurrence of definite or probable stent thrombosis; secondary endpoint was major ad⁃ verse cardiac events (MACEs) including complex end such as recurrent angina, acute non-fatal myocardial infarction, death, target vessel revascularization (TVR); other endpoints include all- cause mortality, cardiac death, myocardial infarc⁃ tion (MI), target lesion revascularization (TLR), non-target vessel revascularization and stroke. Some patients were lost dur⁃ ing follow up, which include 5 in observation group and 26 in control group. Results Patients in observation groups were in⁃ serted with 615 stents while patients in control group were implanted with 614 stents, both groups with average of implanting 1.41 stent / case. There are no statistical significance differences in the primary endpoint [1.4%(6/435) vs 1.8%(8/434), χ2= 0.087], secondary endpoint [12.3% (54/435) vs 10.8%(47/434), χ2=0.524] and other endpoints between the two groups. Con⁃ clusion These data suggest that domestic biodegradable drug-eluting coronary stents (BuMA) are with good long-term safe⁃ ty and efficacy.

Key words: drug-eluting stents, coronary disease, coronary angiography, angioplasty, transluminal, percutaneous coro? nary, stent thrombosis